Christine is currently the Chief Science Officer and Director of Bioengineering at Nano in Austin, Texas. Nano is an intelligent platform that utilizes information from an individual’s everyday life to compile a continuous comprehensive health profile resulting in personalized community support, actionable insights and on-demand products and services. Here she provides strategic oversight and directly orchestrates the company’s approach to tracking and understanding the molecular-level interplay of real-time, behavioral, biological and exposure-based data.
Christine’s deep experience in biotechnology spans disciplines including tissue engineering, drug delivery, molecular biophysics and nanotechnology. Before Nano, Christine served as an advisor to startups focused on emerging developments in science and technology at Powershift Group, a venture development firm that founds and funds technology companies in Austin, Texas.
In 2013, Christine worked for a top-level clinical, regulatory and quality consulting firm that specialized in medical and in vitro diagnostic devices. Previously, she was a research scientist at the University of Texas at Austin where she specialized in molecular biophysics and nanotechnology. Christine also worked as a research scientist in the Department of Nanomedicine at The Methodist Hospital Research Institute, where she was part of the DARPA-funded project to develop BioNanoScaffold for post-traumatic osteoregeneration and the creation of novel nanoparticles for pharmaceutical delivery and targeting. As a recipient of the Waterloo Institute of Nanotechnology Fellowship, she researched HIV treatments at The University of Waterloo in Canada.
Christine has authored several peer-reviewed publications and a chapter for “Nanotechnology Commercialization for Managers and Scientists.” Christine holds a bachelor’s and master’s degree in biomedical engineering from the University of Texas at Austin.